Loading market data...
Latest Top News
Show more
Biocon Biologics Now 100% Biocon-Owned After Landmark Deal
Biocon Ltd will acquire the remaining 23.3% stake in Biocon Biologics for USD 1.17 billion, making it a wholly-owned subsidiary. The deal, funded via cash and share swaps, values BBL at USD 5.5 billion. Analysts see long-term growth potential, with S&P Global placing Biocon Biologics on a positive credit watch.
Stay Ahead – Explore Now! Duck or Rabbit? The Viral Optical Illusion That Claims to Decode Your Personality






